<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Radioimmunotherapy recently afforded convincing results for B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment with antibody specific for B-cell differentiation antigens </plain></SENT>
<SENT sid="1" pm="."><plain>High doses of unlabeled or labeled antibodies are necessary to saturate specific sites on <z:mpath ids='MPATH_458'>normal</z:mpath> B-cells </plain></SENT>
<SENT sid="2" pm="."><plain>We thus developed a new targeting strategy, taking advantage of dual binding cooperativity, to enhance the specificity of the radioactive uptake by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>This approach was evaluated using human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells (Ramos) which express both CD10 and CD20 antigens </plain></SENT>
<SENT sid="4" pm="."><plain>Most <z:mpath ids='MPATH_458'>normal</z:mpath> cells express at most one of these two differentiation antigens but many <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological tumors</z:e>, including most human B type <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> cells, express both </plain></SENT>
<SENT sid="5" pm="."><plain>Cells pretargeted with two bispecific antibodies, one recognizing CD10 and a <z:chebi fb="11" ids="18295">histamine</z:chebi> derivative (HSG), the other recognizing CD20 and the <z:chebi fb="0" ids="35739">DTPA</z:chebi>-<z:chebi fb="1" ids="30430">indium</z:chebi> complex, bind cooperatively radiolabeled mixed-haptens (<z:chebi fb="0" ids="35739">DTPA</z:chebi>-HSG) </plain></SENT>
<SENT sid="6" pm="."><plain>Increased binding (about 5-fold compared to binding to only one of CD10 or CD20 antigens) is observed at 37 degrees C, demonstrating the feasibility of the technique </plain></SENT>
<SENT sid="7" pm="."><plain>This binding enhancement is a slow process, not observed at 4 degrees C </plain></SENT>
<SENT sid="8" pm="."><plain>Such a binding enhancement will increase specificity for targeting isotopes to double antigen positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells compared to nontumor tissue cells bearing only one of them </plain></SENT>
<SENT sid="9" pm="."><plain>This approach might be used to increase <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> irradiation with minimal irradiation of <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
</text></document>